The AJMC® Psoriasis compendium is a comprehensive resource for clinical news and expert insights for the chronic skin disease, which tends to go through cycles where it flares and goes into remission.
May 14th 2024
Botulinum toxin A (BoNT-A) exhibited promising results for nail psoriasis for up to 6 months with a single injection.
Therapeutic Advances in Plaque Psoriasis to Address Unmet Needs in Treatment and Improve Patient Outcomes
1.5 Credits / Dermatology
View More
Managed Care Considerations for Management of Molluscum Contagiosum: Examining Emerging Treatments
1.0 Credit / Dermatology
View More
AJMC® Powered by Patients and Managed Care Insights – More Than a Cosmetic Disease: Vitiligo Treatment Approaches and Raising Awareness of the Disease Burden
1.5 Credits / Dermatology
View More
Advancing Patient Outcomes in Hidradenitis Suppurativa: Updates and Strategies for Managed Care
1.5 Credits / Dermatology
View More
Treatment Gaps in the Management of Generalized Pustular Psoriasis: Enhancing the Role of Managed Care
1.5 Credits / Dermatology, Immunology
View More
Dr Edward W. Cowen on Unmet Needs, Care Considerations Regarding Pustular Psoriasis
February 26th 2022Edward W. Cowen, MD, MHSc, senior clinician and acting branch chief, Dermatology Branch, National Institutes of Health, discusses considerations to address unmet needs and identify appropriate treatment of patients with pustular psoriasis.
Read More
Real-world Study Identifies Several Predictors of Risankizumab Response in Psoriasis
February 14th 2022Risankizumab was shown to be highly effective in patients with moderate to severe psoriasis of tertiary medical centers in Italy, in which response was found to be significantly affected by smoking, and incidence of psoriatic arthritis.
Read More
Early Response to Biologics Linked With Stable Long-term Efficacy in Psoriasis
February 12th 2022More patients with moderate-to-severe psoriasis were found to be early responders to ixekizumab vs ustekinumab; all those who achieved early response were associated with stable skin clearance long-term.
Read More
Dr Edward W. Cowen Addresses Current Management of Pustular Psoriasis
January 30th 2022Edward W. Cowen, MD, MHSc, senior clinician and acting branch chief, Dermatology Branch, National Institutes of Health, discusses treatment considerations for patients with different types of pustular psoriasis.
Watch
Risankizumab Associated With Improved Skin Clearance vs Secukinumab in Moderate to Severe Psoriasis
January 28th 2022Psoriasis Area and Severity Index scores indicated that patients with moderate-to-severe psoriasis had improved skin clearance when treated with risankizumab compared with secukinumab treatment.
Read More
Dr Edward W. Cowen Discusses Pathophysiology, Treatment of Pustular Psoriasis
January 22nd 2022Edward W. Cowen, MD, MHSc, senior clinician and acting branch chief, Dermatology Branch, National Institutes of Health, speaks on cytokines involved in the pathophysiology in pustular psoriasis and off-label therapy use.
Watch
Patients With Psoriatic Disease, Dermatologists Prefer Specialist-Led Care Model for CVD Prevention
January 19th 2022Patients with psoriatic disease and dermatologists reported their preferred strategies to improve cardiovascular disease risk management, with a specialist-led model of care touted by both groups.
Read More
Heightened Depressive, Anxiety Burden Found in Patients With Comorbid Psoriasis and PsA
January 15th 2022Patients with comorbid psoriasis and psoriatic arthritis exhibited significantly higher rates of depression and anxiety vs those with psoriasis alone, whereas lifetime suicidality prevalence was not different between the 2 groups but still heightened compared with the general population.
Read More
Adjuvant Ultraviolet-Based Therapy More Effective vs Monotherapy in Psoriasis
January 12th 2022Patients with psoriasis exhibited superior efficacy outcomes when treated with ultraviolet (UV)-based phototherapy plus other adjuvant therapies vs UV monotherapy, with similar safety profiles shown for both approaches.
Read More
Psoriasis Severity, Treatment Outcomes Differ Across US Regions
December 27th 2021Psoriasis severity and treatment outcomes were found to differ across US geographic regions, in which the East South Central and West South Central regions were associated with the greatest frequencies of very severe disease burden and decreased likelihood of achieving targeted response within 6 months of initiating biologic therapy.
Read More
Study Finds No Standardized Treatment, Continued Health Care Utilization in Pustular Psoriasis
December 18th 2021A case series of patients with pustular psoriasis indicated a lack of standardized treatment and continued health care utilization, in which men were at greater risk of an emergency department or hospital encounter.
Read More